Diabetes in Canada: Facts and figures from a public health perspective

Chapter 5 – Diabetes in children and youth

Introduction

Diabetes is one of the most common chronic diseases among children and youth. In 2008/09, the CCDSS reported 3,287 new cases of diagnosed diabetes (including both type 1 and type 2) among Canadians aged one to 19 years, bringing the total number of cases in children and youth to 25,693 (representing a prevalence rate of 0.3%) (Chapter 1, Table 1-1).

Historically, all cases of diabetes in young individuals were believed to be type 1 diabetes. However, for the last two decades, type 2 diabetes has been on the rise globally in this population. Currently, no population-based surveillance study has confirmed the ratio between the two types of the disease in children and youth in Canada. However, one study from British Columbia developed an algorithm to distinguish between type 1 and type 2 cases in administrative data, and estimated that approximately 90% of the cases among children and youth aged one to 19 years were of type 1 diabetes and 10% were of type 2 diabetes in 2006/07.¹ As the rates of obesity increase among children and youth, the rates of type 2 diabetes also increase. Therefore, the ratio of type 1 to type 2 in this population is likely to be impacted.²

Research suggests that both type 1 and type 2 diabetes are increasing worldwide in youth.³ As both forms of diabetes are lifelong diseases, the early onset of either type increases the risk of related complications later in life, with lifelong implications for those with the disease and their families, as well as for the health care system and the Canadian economy. Although it is currently only possible to prevent type 2 diabetes, optimal management of both type 1 and type 2 diabetes is of primary importance to prevent negative consequences of either disease.

Type 1 diabetes

Most cases of type 1 diabetes are diagnosed during childhood and adolescence, and it is recognized that type 1 diabetes remains the predominant form of the disease in this population.⁴ The onset can occur as early as during the first year of life, but generally the onset is most common between ten and 14 years of age.⁵ No consistent gender pattern for the incidence of type 1 diabetes in youth was observed.⁶

Estimates of the number of children and youth who have type 1 diabetes in Canada are limited. Currently a national estimate is not available, and existing estimates vary widely accross provinces. Between 1989 and 2000, the annual incidence of type 1 diabetes among children aged 18 years and under in Quebec was 15 cases per 100,000 children.⁷ Newfoundland and Labrador reported one of the highest incidence rates of type 1 diabetes in the world; for the period between 1987 and 2005, incidence among children aged less than 15 years was identified as 35 cases per 100,000 children. In children aged less than five years, boys (31.6 cases per 100,000 children aged less then five) were more likely to be affected than girls (19.1 cases per 100,000 children aged less than five).⁸

Rates of type 1 diabetes among children and youth have been on the rise globally.⁹ Based on study analyses, Canada was found to have one of the highest incidence rates of type 1 diabetes for children under 14 years of age.^6;10 In Canada, the average relative increase in incidence rates has been estimated at 5.1% per year between 1990 and 1999.⁶ Children under the age of five were the fastest growing segment of the population with type 1 diabetes.^6;10;11

Risk factors for type 1 diabetes

Type 1 diabetes is a multifactorial condition, characterized by the presence of autoimmunity against insulin producing cells. Although researchers have not yet identified all of the factors causing type 1 diabetes and the interactions among them, they believe genetic factors and environmental triggers are involved.^9;12 The increasing trend of type 1 diabetes observed in many countries is believed to be associated with a number of factors, such as changes in early feeding patterns, early growth in the first year of life, and hygiene practices such as the use of antibacterial disinfectants, among other influences. Other findings that support the theory of genetic and environmental associations include:

• Type 1 diabetes is most common among children and youth of northern European descent.¹³
• First-degree relatives (parents, offspring, siblings) of individuals with type 1 diabetes have a tenfold greater risk of developing type 1 diabetes than the rest of the population.¹⁴ In particular, children of fathers with type 1 diabetes are at a greater risk of developing type 1 diabetes than children of mothers with the disease.¹⁵
• No single infection has been linked to an increase in type 1 diabetes,¹⁶ but viruses such as enteroviruses¹⁷ and dietary microbial toxins^18;19 may be factors in the development of type 1 diabetes.
• Studies have identified a number of factors that might reduce the risk of developing type 1 diabetes, such as breastfeeding and vitamin D. Less exposure to the sun^20;21 (a source of vitamin D) and vitamin D deficiency^22-25 are associated with higher rates of type 1 diabetes. Some research has suggested that breastfeeding has a protective effect against the development of type 1 diabetes,^26;27 while short duration of breastfeeding has been implicated as a predisposing factor,²⁸ especially in children at increased genetic risk.²⁹
• It is hypothesized that obesity may promote the development of insulin resistance, which in turn results in the autoimmune destruction of beta-cells trying to compensate for the insulin imbalance.^30;31

Short- and long-term complications of type 1 diabetes

The long-term complications of type 1 diabetes³² are the same as those for type 2 diabetes, including cardiovascular disease, retinopathy, and nephropathy (Chapter 2). However, because type 1 diabetes is most commonly diagnosed in childhood, there is an increased risk of long-term complications at earlier ages compared to individuals living with type 2 diabetes. In addition to the long-term complications of diabetes, people with type 1 diabetes are at greater risk of immediate and acute complications because of their reliance on an external source of insulin. The administration of too much or too little insulin, resulting in extremes in glycemic levels, can lead to life-threatening complications caused by hypoglycemia and DKA.

Hypoglycemia occurs when excess insulin in the blood leads to extremely low glycemic levels. In addition to insulin dosage errors or incorrect estimations, common causes include missed meals, illness, and increased physical activity without a corresponding reduction in insulin or increase in carbohydrate consumption.³³ Episodes of severe or recurrent hypoglycemia, especially before the age of five years, may affect cognitive functions and result in learning problems.^34;35 Severe hypoglycemic episodes have been shown to affect performance and verbal IQ in children with type 1 diabetes.^36;37 DKA, often referred to as diabetic coma, results from hyperglycemia due to a lack of insulin. It is the leading cause of death and permanent disability among children with diabetes.³⁸ DKA is a preventable complication that occurs at the onset of 15% to 67% of type 1 diabetes cases.^39-41 Among children with established type 1 diabetes, most DKA episodes are associated with insulin omission or treatment error.^42;43

More frequent emergency department admissions and hospitalizations,⁴⁴ decreased quality of life and increased mental health issues such as depression, anxiety and eating disorders,⁴⁵ are also more common among children with type 1 diabetes. Fortunately, treatment can prevent acute complications and reduce the development of long-term complications.⁴⁶

Management strategies for children and youth with type 1 diabetes

Intensive daily management of glycemic levels is essential for reducing short- and long-term complications of type 1 diabetes.^47-49 In contrast to the fixed glycemic targets provided for adults, targets for children vary by age.⁵⁰

Meticulous balancing of diet and physical activity with insulin intake is the core of type 1 diabetes management. In Canada, two strategies for administering insulin that are commonly used to manage type 1 diabetes are multiple daily injections (MDI) of insulin using syringes or pen devices, and continuous subcutaneous insulin infusion (CSII) from an insulin pump. An insulin pump, which is a programmable medical device worn outside the body, aims to mimic the natural insulin delivery of the pancreas. It continuously infuses insulin based on the individual's body needs over the course of a 24-hour cycle. Studies have shown that CSII reduces HbA1c levels significantly more than MDI, and that CSII reduces rates of severe hypoglycemia and contributes to a greater quality of life for patients.⁵¹ Optimal management of diabetes implies that the most adequate tools and technologies for each patient should be made available and accessible to those who need it.

Several novel therapies are currently being tested as cures for type 1 diabetes, including pancreatic islet transplantation and the development of an artificial pancreas.⁵² Pancreatic islet transplantation was previously limited by the lack of donors and immune rejection of graft, but cell replacement therapy now holds substantial promise with the use of stem cells.⁵³ Developments in pump therapy with the use of continuous glucose monitoring have advanced diabetes care, and an artificial pancreas could be produced in the foreseeable future.^54;55

Challenges in management

Children and youth with type 1 diabetes face many of the same challenges in managing their disease as do adults, but face additional issues specific to their age.

Developmental stages of childhood

The physiological, psychological, social and emotional changes that occur as a child ages can be challenging for the management of type 1 diabetes. As a child grows, insulin requirements change and management strategies must be adapted accordingly. During the earlier stages of a child's growth and development, parents inevitably have more responsibility for the management of glycemic levels. As children mature, they become more capable of taking on these responsibilities.^56-58

Adolescence can be a particularly difficult time for management of glycemic levels as adolescents take on responsibility for the management of their disease at the same time as hormonal changes affect glycemic levels and impact insulin requirements.^34;35;50 Body weight issues and eating disorders, more frequent among adolescent females than males, may incite some adolescents to adopt practices that are detrimental to the management of glycemic levels, such as omitting or modifying insulin doses as a means to control their weight.^45;59

The stress of caring for a child with type 1 diabetes can also strain the health of a parent.^56;57 Parents or guardians of children with type 1 diabetes live with the daily demands of round-the-clock monitoring of glycemic levels in their child. Daily activities include administering insulin injections, managing diets and monitoring physical activity levels.

Care in schools

Because children and youth spend a great deal of their daytime hours in school, this setting must meet the needs of children and youth with type 1 diabetes.^60-65 Levels of support and care adjusted to the age and development of a child are essential for the proper management of type 1 diabetes in the school setting. In Quebec for example, guidelines on interventions in school settings for children living with type 1 diabetes have recently been published. This protocol describes the role and responsibilities of the different personnel involved, including parents, school nurses, the school principal and other educators in charge of the children, as well as the children themselves.⁶⁶ Nurses, teachers and other personnel who are trained to help monitor and support the needs of children with type 1 diabetes can make a significant difference in the quality of a child's diabetes management and in ensuring that the child's health and performance in school are not compromised. While preventive measures are paramount, access to Glucagon is essential when a severe hypoglycaemic event occurs. Glucagon is not yet universally available in schools across Canada.

Type 2 diabetes

Historically, type 2 diabetes was viewed as an adult-onset disease, and all cases of diabetes in young people were assumed to be of type 1. Although still not common among children and youth, type 2 diabetes is now known to occur in this group, typically developing during or just after puberty, between the ages of ten and 19 years.⁵ The development of type 2 diabetes in children and youth is not well understood. The progression from impaired glucose tolerance to type 2 diabetes is faster in children than in adults.^67;68 Also, acute complications, such as DKA, most commonly associated with type 1 diabetes, appear to be more common in newly diagnosed children and youth with type 2 diabetes than among adults.⁶⁹ Contrary to the gender pattern observed in the adult population, type 2 diabetes seems more frequent among female children and youth than their male counterparts.⁷⁰

In the last two decades, type 2 diabetes has been on the rise among children and youth globally.⁷¹ Type 2 diabetes in children was first brought to the attention of the scientific community in Canada when a description of 12 Aboriginal children in Manitoba with type 2 diabetes was published in 1992.⁷² Since then, several studies in Canada^70;73;74 and internationally^5;13;75 have reported increases in type 2 diabetes in children and youth. In the United States, the incidence of type 2 diabetes is 8.1 cases per 100,000 person-years in children aged ten to 14 years, and 11.8 cases per 100,000 person-years in those aged 15 to 19 years.⁵ In the United Kingdom, the incidence of type 2 diabetes in children less than 17 years of age was at least 0.53 cases per 100,000 children per year.⁷⁵

In Canada, trends in type 2 diabetes in children and youth have been reported for specific populations and provinces. In 2004, Manitoba reported 35 to 40 new cases of childhood type 2 diabetes, representing about 30% of all new cases of childhood diabetes in Manitoba annually.⁷⁶ Between 2000 and 2002, the Diabetes Care Program of Nova Scotia reported 5.4 new cases of type 2 diabetes per 100,000 children under the age of 19 years. A higher proportion of 10.5 new cases per 100,000 children was reported in children between the ages of ten and 19 years.⁷⁷ A Canada-wide population-based surveillance study of new onset childhood type 2 diabetes was conducted from 2006 to 2008.⁶⁹ In this study, 227 cases of type 2 diabetes were identified in a two-year period, which was extrapolated to a minimum national incidence rate of 1.54 new cases per 100,000 children under the age of 18 years. In turn, this incidence rate would translate into at least 113 new cases of childhood type 2 diabetes diagnosed in Canada every year. This study found differences in prevalence across Canada, which likely reflect differences in the proportions of children of First Nations or certain ethnic descent who are at higher risk of developing type 2 diabetes. The incidence of children and youth aged 18 and under with type 2 diabetes was higher among Aboriginal children and youth than among Asian, African and Caribbean, and Caucasian children and youth. Similar results were reported in international studies.^5;78 An earlier retrospective study conducted in the Toronto area also showed an overrepresentation of Asian and African children with type 2 diabetes.⁷⁰

Risk factors for type 2 diabetes

The factors that increase the probability that a child will develop type 2 diabetes are the same risk factors seen in adults (Chapter 4). They include overweight and obesity, physical inactivity, a family history of diabetes, certain ethnicities, maternal gestational diabetes and insulin resistance.

Obesity

A recent Canadian surveillance study found that 95% of children newly diagnosed with type 2 diabetes were obese.⁶⁹ Overall, in the last 25 years, rates of obesity in children and youth have been increasing rapidly throughout the world. In Canada, the number of obese children aged two to 17 years more than doubled, from 3% in 1978-1979 to 8% in 2004.⁷⁹ The emergence of type 2 diabetes in children and youth has occurred concurrently with the rise in rates of childhood obesity.

Family history

Children and youth with a family history of type 2 diabetes show reductions in insulin sensitivity at a younger age than children with no family history.⁸⁰ Studies show that more than 75% of children and youth with type 2 diabetes have at least one relative with the disease.⁸¹ In Canada, more than 90% of children and youth with type 2 diabetes have a first or a second degree family member with the disease.^69;70

Ethnicity

Children from some ethnic groups (First Nations, African/Caribbean, Hispanic, and South Asian) are at higher risk of earlier onset of type 2 diabetes.^13;72 A majority of Canadian children with type 2 diabetes (75%) belong to a high-risk ethnic group.⁶⁹

Puberty

Individuals aged 13 to 17 going through puberty may be more vulnerable to the development of type 2 diabetes.^69;75 Among Canadians under age 18, type 2 diabetes developed at an average age of 13.7 years, with only 8% of children developing it before ten years of age.⁶⁹

Short- and long-term complications of type 2 diabetes

Studies show that diabetes-related complications develop more rapidly in children and youth with type 2 diabetes than in adults.^82-85 Complications also appear to develop earlier in children and youth with type 2 diabetes than in those with type 1 diabetes.^86;87

Typically, children and adolescents with type 2 diabetes face complications from both diabetes and obesity. They have been shown to have an early and increased risk of cardiovascular disease and its risk factors.⁸⁸ One study found that hypertension was up to eight times more common in youth with type 2 diabetes than in those with type 1.⁸⁹ In a study of children from the United States with type 2 diabetes, between 18% and 61% had hypercholesterolemia, and between 10% and 32% had hypertension. In a recent study of Canadian children with type 2 diabetes, 45% had dyslipidemia and 28% had hypertension at diagnosis. In addition, 37% of children and youth with a new diagnosis of type 2 diabetes already had at least one co-morbid condition related to their diabetes or obesity, at an average age of 13.7 years.⁶⁹

The development of type 2 diabetes early in life inevitably leads to increased costs to the health care system, as diabetes management and the treatment of its complications require lifelong attention.

Management strategies for children and youth with type 2 diabetes

Lifestyle change is the cornerstone of type 2 diabetes management in children and youth, although medication is sometimes necessary. Children and youth with type 2 diabetes are optimally managed when an interdisciplinary health care team helps the achievement of treatment goals.⁵⁰ Education of the patient should be age-appropriate and culturally sensitive, and should focus on the lifestyle and health behaviours of the whole family.

A critical component in the management of type 2 diabetes is screening for, and prevention of, complications. The Canadian Diabetes Association clinical practice guidelines recommend that children and youth with type 2 diabetes be screened for hypertension at every clinical visit, and that they be screened for other risk factors for type 2 diabetes including hypercholesterolemia, non-alcoholic fatty liver disease, nephropathy and retinopathy when they are first diagnosed and annually thereafter.⁵⁰

In Canada, insulin and metformin (an oral medication) are the only medications approved for use with children and youth with type 2 diabetes.⁹⁰ There is limited information on the effectiveness and safety of other oral hypoglycemic medications in children and youth with type 2 diabetes. Children and youth who have high glycemic levels that result in a diabetic coma or persistent hyperglycemia are often placed on insulin therapy.⁹¹

Limitations of diabetes surveillance in children and youth

With both types of diabetes on the rise, a global effort is underway to conduct population studies to determine the incidence and prevalence of type 1 and type 2 diabetes in children and youth. At this time, there is limited population-based data in Canada to document the trends in childhood diabetes or the demographic, behavioural, clinical and socioeconomic characteristics of this population. Studies that do exist tend to focus on specific subgroups and are not population-based.

Clinically, it may be difficult to distinguish between type 1 and type 2 diabetes. Since type 1 diabetes remains the predominant form in children and youth, cases of type 2 diabetes are sometimes misclassified. This means there may be a substantial number of children and youth whose type 2 diabetes has remained undiagnosed, or who have been misdiagnosed with type 1 diabetes. Currently, the CCDSS does not distinguish between type 1 and type 2 diabetes. However, studies are underway to expand CCDSS methodology for this purpose. For example, a study in British Columbia has been successful in differentiating type 1 and type 2 diabetes within administrative data in persons aged less than 19 years by adapting CCDSS methodology through the application of algorithms that use demographic and drug treatment data.⁹²

Looking ahead

Effective national surveillance is vital in order to gain a better understanding of the magnitude, characteristics and public health consequences of type 1 and type 2 diabetes in Canadian children and youth. Type 1 diabetes is not yet preventable. However, healthy weight and regular physical activity remain key to the reduction of type 2 diabetes in this population and contribute directly to the optimal management of both types of diabetes. Since children and youth diagnosed with type 1 and type 2 diabetes will live with the disease for life, effective management is a critical step toward reducing their risk of complications and improving their quality of life.

In that regard, the endorsement of the Curbing Childhood Obesity: A Federal, Provincial and Territorial Framework for Action to Promote Healthy Weights by federal, provincial and territorial Ministers of Health in 2010 signalled a commitment from these governments to work together, with partners across and outside the health sector, to take action on promoting healthy weights among children. This framework is comprised of three key strategies: "making childhood overweight and obesity a collective priority for action"; "coordinating efforts on three key policy priorities" (supportive environments, early action and nutritious foods); and "measuring and reporting on collective progress". Currently, actions are being undertaken as part of each strategy by the Ministers of Health, their governments and other sectors, to address childhood obesity and promote healthy weights.

Reference list

1. Amed S, Nuernberger K, McCrea P. et al. Status report on the British Columbia Paediatric Diabetes Program. Shazhan Amed, editor. Vancouver, BC: Provincial Health Services Authority; 2010.
2. Botero D, Wolfsdorf JI. Diabetes mellitus in children and adolescents. Arch Med Res. 2005;36(3):281-290.
3. Lipton RB. Incidence of diabetes in children and youth - Tracking a moving target.
   JAMA. 2007;297(24):2760-2762.
   
4. Ekoé J, Zimmet P. Diabetes mellitus: Diagnosis and classification. In: Ekoe J-M, Zimmet P, Williams R, eds. The epidemiology of diabetes mellitus: An international perspective. Chichester: John Wiley & Sons; 2011;11-29.
5. Dabelea D, Bell RA, D'Agostino RB, et al. Incidence of diabetes in youth in the United States. JAMA. 2007;297(24):2716-2724.
6. DIAMOND Project Group. Incidence and trends of childhood Type 1 diabetes worldwide 1990-1999. Diabet Med. 2006;23(8):857-866.
7. Legault L, Polychronakos C. Annual incidence of type 1 diabetes in Quebec between 1989-2000 in children. Clin Invest Med. 2006;29(1):10-13.
8. Newhook LA, Grant M, Sloka S et al. Very high and increasing incidence of type 1 diabetes mellitus in Newfoundland and Labrador, Canada. Pediatr Diabetes. 2008;9(3 Pt 2):62-68.
9. Vehik K, Dabelea D. The changing epidemiology of type 1 diabetes: Why is it going through the roof? Diabetes Metab Res Rev. 2011;27(1):3-13.
10. Karvonen M, Viik-Kajander M, Moltchanova E, Libman I, LaPorte R, Tuomilehto J. Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes Care. 2000;23(10):1516-1526.
11. Patterson CC, Dahlquist GG, Gyrs E, Green A, Soltqsz G. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: A multicentre prospective registration study. Lancet; 373(9680):2027-2033.
12. Beyhan H, Leslie RD. Type 1 diabetes mellitus. In: Weetman AP, ed. Autoimmune diseases in endocrinology (Contemporary endocrinology). Totowa, NJ: Humana Press; 2008;275-299.
13. Bell RA, Mayer-Davis EJ, Beyer JW et al. Diabetes in non-Hispanic white youth: Prevalence, incidence, and clinical characteristics: The SEARCH for Diabetes in Youth Study. Diabetes Care. 2009;32(Suppl 2):S102-S111.
14. Davidson JK, ed. Clinical diabetes mellitus. A problem-oriented approach. 2 ed. New York, NY: Thieme Medical Publishers, 2000.
15. Weires MB, Tausch B, Haug PJ, Edwards CQ, Wetter T, Cannon-Albright LA. Familiality of diabetes mellitus. Exp Clin Endocrinol Diabetes. 2007;115(10):634-640.
16. Cooke A. Review series on helminths, immune modulation and the hygiene hypothesis: How might infection modulate the onset of type 1 diabetes? Immunology. 2009;126(1):12-17.
17. Richardson SJ, Willcox A, Bone AJ, Foulis AK, Morgan NG. The prevalence of enteroviral capsid protein vp1 immunostaining in pancreatic islets in human type 1 diabetes. Diabetologia. 2009;52(6):1143-1151.
18. Rayfield EI, Poon M. Viral infection and other factors. In: Davidson JK, ed. Clinical diabetes mellitus: A problem oriented approach. 3rd ed. New York, NY: Thieme Medical Publishers; 2000;59-68.
19. Neu J, Lorca G, Kingma SDK, Triplett EW. The intestinal microbiome: Relationship to type 1 diabetes. Endocrinol Metab Clin North Am. 2010;39(3):563-571.
20. Mohr SB, Garland CF, Gorham ED, Garland FC. The association between ultraviolet B irradiance, vitamin D status and incidence rates of type 1 diabetes in 51 regions worldwide. Diabetologia. 2008;51(8):1391-1398.
21. Grant WB. Hypothesis - ultraviolet-B irradiance and vitamin D reduce the risk of viral infections and thus their sequelae, including autoimmune diseases and some cancers. Photochem Photobiol. 2008;84(2):356-365.
22. Zipitis CS, Akobeng AK. Vitamin D supplementation in early childhood and risk of type 1 diabetes: A systematic review and meta-analysis. Arch Dis Child. 2008;93(6):512-517.
23. Danescu LG, Levy S, Levy J. Vitamin D and diabetes mellitus. Endocrine. 2009;35(1):11-17.
24. Merriman TR. Type 1 diabetes, the A1 milk hypothesis and vitamin D deficiency. Diabetes Res Clin Pract. 2009;83(2):149-156.
25. Holick MF. Diabetes and the vitamin D connection. Curr Diab Rep. 2008;8(5):393-398.
26. Borch-Johnsen K, Joner G, Mandrup-Poulsen T et al. Relation between breast-feeding and incidence rates of insulin-dependent diabetes mellitus. A hypothesis. Lancet. 1984;2(8411):1083-1086.
27. Shehadeh N, Shamir R, Berant M, Etzioni A. Insulin in human milk and the prevention of type 1 diabetes. Pediatr Diabetes. 2001;2(4):175-177.
28. Gerstein HC. Cow's milk exposure and type I diabetes mellitus. A critical overview of the clinical literature. Diabetes Care. 1994;17(1):13-19.
29. Akerblom HK, Virtanen SM, Ilonen J et al. Dietary manipulation of beta cell autoimmunity in infants at increased risk of type 1 diabetes: A pilot study. Diabetologia. 2005;48(5):829-837.
30. Hypponen E, Virtanen SM, Kenward MG, Knip M, Akerblom HK. Obesity, increased linear growth, and risk of type 1 diabetes in children. Diabetes Care. 2000;23(12):1755-1760.
31. Pozzilli P, Guglielmi C, Caprio S, Buzzetti R. Obesity, autoimmunity, and double diabetes in youth. Diabetes Care. 2011;34(Suppl 2):S166-S170.
32. Melendez-Ramirez LY, Richards RJ, Cefalu WT. Complications of type 1 diabetes. Endocrinol Metab Clin North Am. 2010;39(3):625-640.
33. Rewers A. Epidemiology of acute complications: Diabetic ketoacidosis, hyperglycemic hyperosmolar state and hypoglycemia. In: Ekoe J-M, Rewers M, Williams R, Zimmet P, eds. The epidemiology of diabetes mellitus. 2^nd ed. West Sussex, UK: Wiley-Blackwell; 2008;577-602.
34. Desrocher M, Rovet J. Neurocognitive correlates of type 1 diabetes mellitus in childhood. Child Neuropsychol. 2004;10(1):36-52.
    
35. Naguib JM, Kulinskaya E, Lomax CL, Garralda ME. Neuro-cognitive performance in children with type 1 diabetes - A meta-analysis. J Pediatr Psychol. 2009;34(3):271-282.
36. Hannonen R, Tupola S, Ahonen T, Riikonen R. Neurocognitive functioning in children with type-1 diabetes with and without episodes of severe hypoglycaemia. Dev Med Child Neurol. 2003;45(4):262-268.
37. Ghetti S, Lee JK, Sims CE, Demaster DM, Glaser NS. Diabetic ketoacidosis and memory dysfunction in children with type 1 diabetes. J Pediatr. 2010;156(1):109-114.
38. Dahlquist G, Kallen B. Mortality in childhood-onset type 1 diabetes: A population-based study. Diabetes Care. 2005;28(10):2384-2387.
39. Rewers A, Klingensmith G, Davis C et al. Presence of diabetic ketoacidosis at diagnosis of diabetes mellitus in youth: The Search for Diabetes in Youth Study. Pediatrics. 2008;121(5):e1258-e1266.
40. Komulainen J, Lounamaa R, Knip M, Kaprio EA, Akerblom HK. Ketoacidosis at the diagnosis of type 1 (insulin dependent) diabetes mellitus is related to poor residual beta cell function. Childhood Diabetes in Finland Study Group. Arch Dis Child. 1996;75(5):410-415.
41. Levy-Marchal C, Papoz L, de Beaufort C et al. Clinical and laboratory features of type 1 diabetic children at the time of diagnosis. Diabet Med. 1992;9(3):279-284.
42. Reda E, Von RA, Dunn P. Metabolic control with insulin pump therapy: The Waikato experience. N Z Med J. 2007;120(1248):U2401.
43. Mbugua PK, Otieno CF, Kayima JK, Amayo AA, McLigeyo SO. Diabetic ketoacidosis: Clinical presentation and precipitating factors at Kenyatta National Hospital, Nairobi. East Afr Med J. 2005;82(Suppl 12):S191-S196.
44. Hunger-Dathe W, Braun A, Muller UA, Schiel R, Femerling M, Risse A. Insulin pump therapy in patients with Type 1 diabetes mellitus: Results of the Nationwide Quality Circle in Germany (ASD) 1999-2000. Exp Clin Endocrinol Diabetes. 2003;111(7):428-434.
45. Jones JM, Lawson ML, Daneman D, Olmsted MP, Rodin G. Eating disorders in adolescent females with and without type 1 diabetes: Cross sectional study. BMJ. 2000;320(7249):1563-1566.
46. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications and Pittsburgh Epidemiology of Diabetes Complications Experience (1983-2005). Arch Intern Med. 2009;169(14):1307-1316.
47. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
48. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643-2653.
49. Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. JAMA. 1996;276(17):1409-1415.
50. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008;32(Suppl 1):S1-S201.
51. Misso ML, Egberts KJ, Page M, O'Connor D, Shaw J. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2010;(1):CD005103.
52. Robertson RP. Update on transplanting beta cells for reversing type 1 diabetes. Endocrinol Metab Clin North Am. 2010;39(3):655-667.
53. Ichii H, Ricordi C. Current status of islet cell transplantation. J Hepatobiliary Pancreat Surg. 2009;16(2):101-112.
54. Sherr J, Tamborlane WV. Past, present, and future of insulin pump therapy: Better shot at diabetes control. Mt Sinai J Med. 2008;75(4):352-361.
55. Aye T, Block J, Buckingham B. Toward closing the loop: An update on insulin pumps and continuous glucose monitoring systems. Endocrinol Metab Clin North Am. 2010;39(3):609-624.
56. Silverstein J, Klingensmith G, Copeland K et al. Care of children and adolescents with type 1 diabetes: A statement of the American Diabetes Association. Diabetes Care. 2005;28(1):186-212.
57. Soltesz G. Diabetes in the young: A paediatric and epidemiological perspective.
    Diabetologia. 2003;46(4):447-454.
    
58. Atkinson MA, Eisenbarth GS. Type 1 diabetes: New perspectives on disease pathogenesis and treatment. Lancet. 2001;358(9277):221-229.
59. Ackard DM, Vik N, Neumark-Sztainer D, Schmitz KH, Hannan P, Jacobs DR. Disordered eating and body dissatisfaction in adolescents with type 1 diabetes and a population-based comparison sample: Comparative prevalence and clinical implications. Pediatric Diabetes. 2008;9(4 Pt 1):312-319.
60. Canadian Diabetes Association. Standards of care for students with type I diabetes in school. 2008. Accessed September 7, 2011.
61. Canadian Diabetes Association. Kids with diabetes in your care. 2008. Accessed September 7, 2011.
62. Children with Diabetes. Accessed 2009.
63. Coyea M, Paquin R, Proulx M-J. L'école et nos enfants diabétiques de type 1. 2007.
64. Geoffroy L, Gonthier M. Le diabète chez l'enfant. Montréal, QC: Éditions de l'Hôpital Sainte-Justine; 2003.
65. Juvenile Diabetes Research Foundation International. School Advisory Toolkit for Families 2008. Accessed 2009.
66. Dubé N, Lachance N, Lapointe L, Pelletier J, Rivet L. Protocole d'intervention en milieu scolaire pour les élèves atteints de diabète de type 1. Québec, QC: Santé et des Services sociaux du Québec; 2011.
67. Weiss R, Taksali SE, Tamborlane WV, Burgert TS, Savoye M, Caprio S. Predictors of changes in glucose tolerance status in obese youth. Diabetes Care. 2005;28(4):902-909.
68. Edelstein SL, Knowler WC, Bain RP et al. Predictors of progression from impaired glucose tolerance to NIDDM: An analysis of six prospective studies. Diabetes. 1997;46(4):701-710.
69. Amed S, Dean HJ, Panagiotopoulos C et al. Type 2 diabetes, medication-induced diabetes, and monogenic diabetes in Canadian children: A prospective national surveillance study. Diabetes Care. 2010;33(4):786-791.
70. Zdravkovic V, Daneman D, Hamilton J. Presentation and course of type 2 diabetes in youth in a large multi-ethnic city. Diabet Med. 2004;21(10):1144-1148.
71. Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr. 2005;146(5):693-700.
72. Dean HJ, Mundy RL, Moffatt M. Non-insulin-dependent diabetes mellitus in Indian children in Manitoba. CMAJ. 1992;147(1):52-57.
73. Blanchard JF, Ludwig S, Wajda A et al. Incidence and prevalence of diabetes in Manitoba, 1986-1991. Diabetes Care. 1996;19(8):807-811.
74. Curtis JR, Daneman D. Diabetes in children. In: Hux J, Booth GL, Slaughter P, Laupacis A, eds. Diabetes in Ontario: An ICES practice atlas. Toronto, ON: Institute for Clinical Evaluative Sciences; 2003: 12.219-12.230.
75. Haines L, Wan KC, Lynn R, Barrett TG, Shield JP. Rising incidence of type 2 diabetes in children in the U.K. Diabetes Care. 2007;30(5):1097-1101.
76. Winnipeg Regional Health Authority. Diabetes education resource for children and adolescents (DER-CA) 2004 annual report. 2004.
77. Incidence of type 2 diabetes in youth <19 years of age in Nova Scotia: 1992-2002. ESPE/LWPES 7th Joint Meeting Paediatric Endocrinology. Lyon, France; 2005.
78. Maple-Brown LJ, Sinha AK, Davis EA. Type 2 diabetes in indigenous Australian children and adolescents. J Paediatr Child Health. 2010;46(9):487-490.
79. Shields M. Overweight Canadian children and youth. Ottawa, ON: Statistics Canada; 2005. Accessed September 6, 2011.
80. Arslanian SA, Bacha F, Saad R, Gungor N. Family history of type 2 diabetes is associated with decreased insulin sensitivity and an impaired balance between insulin sensitivity and insulin secretion in white youth. Diabetes Care. 2005;28(1):115-119.
81. Silverstein JH, Rosenbloom AL. Type 2 diabetes in children. Curr Diab Rep. 200;1(1):19-27.
82. Pavkov ME, Bennett PH, Knowler WC, Krakoff J, Sievers ML, Nelson RG. Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians. JAMA. 2006;296(4):421-426.
83. Ettinger LM, Freeman K, Martino-Nardi JR, Flynn JT. Microalbuminuria and abnormal ambulatory blood pressure in adolescents with type 2 diabetes mellitus. J Pediatr. 2005;147(1):67-73.
84. Fagot-Campagna A, Nelson RG, Knowler WC et al. Plasma lipoproteins and the incidence of abnormal excretion of albumin in diabetic American Indians: The Strong Heart Study. Diabetologia. 1998;41(9):1002-1009.
85. Yokoyama H, Okudaira M, Otani T et al. High incidence of diabetic nephropathy in early-onset Japanese NIDDM patients. Risk analysis. Diabetes Care. 1998;21(7):1080-1085.
86. Yokoyama H, Okudaira M, Otani T et al. Higher incidence of diabetic nephropathy in type 2 than in type 1 diabetes in early-onset diabetes in Japan. Kidney Int. 2000;58(1):302-311.
87. Eppens MC, Craig ME, Cusumano J et al. Prevalence of diabetes complications in adolescents with type 2 compared with type 1 diabetes. Diabetes Care. 2006;29(6):1300-1306.
88. Gungor N, Thompson T, Sutton-Tyrrell K, Janosky J, Arslanian S. Early signs of cardiovascular disease in youth with obesity and type 2 diabetes. Diabetes Care. 2005;28(5):1219-1221.
89. Pinhas-Hamiel O, Zeitler P. Acute and chronic complications of type 2 diabetes mellitus in children and adolescents. Lancet. 2007;369(9575):1823-1831.
90. Jones KL, Arslanian S, Peterokova VA, Park JS, Tomlinson MJ. Effect of metformin in pediatric patients with type 2 diabetes: A randomized controlled trial. Diabetes Care. 2002;25(1):89-94.
91. Urakami T, Kubota S, Nitadori Y, Harada K, Owada M, Kitagawa T. Annual incidence and clinical characteristics of type 2 diabetes in children as detected by urine glucose screening in the Tokyo metropolitan area. Diabetes Care. 2005;28(8):1876-1881.
92. Vanderloo SE, Johnson JA, Reimer K et al. Validation of classification algorithms for childhood diabetes identified from administrative data. Pediatr Diabetes [published online ahead of print July 19 2007]. doi: 10.1111/j.1399-5448.2011.00795.x